Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes
Open accessThe DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
We report a group of patients presenting with a progressive dementia syndrome characterized by predominant dysfunction in core executive functions, relatively young age of onset and positive biomarkers for Alzheimer’s pathophysiology. Atypical frontal, dysexecutive/behavioural variants and early-onset variants of Alzheimer’s disease have been previously reported, but no diagnostic criteria exist for a progressive dysexecutive syndrome. In this retrospective review, we report on 55 participants diagnosed with a clinically defined progressive dysexecutive syndrome with 18F-fluorodeoxyglucose-positron emission tomography and Alzheimer’s disease biomarkers available. Sixty-two per cent of participants were female with a mean of 15.2 years of education. The mean age of reported symptom onset was 53.8 years while the mean age at diagnosis was 57.2 years. Participants and informants commonly referred to initial cognitive symptoms as ‘memory problems’ but upon further inquiry described problems with core executive functions of working memory, cognitive flexibility and cognitive inhibitory control. Multi-domain cognitive impairment was evident in neuropsychological testing with executive dysfunction most consistently affected. The frontal and parietal regions which overlap with working memory networks consistently demonstrated hypometabolism on positron emission tomography. Genetic testing for autosomal dominant genes was negative in all eight participants tested and at least one APOE ε4 allele was present in 14/26 participants tested. EEG was abnormal in 14/17 cases with 13 described as diffuse slowing. Furthermore, CSF or neuroimaging biomarkers were consistent with Alzheimer’s disease pathophysiology, although CSF p-tau was normal in 24% of cases. Fifteen of the executive predominate participants enrolled in research neuroimaging protocols and were compared to amnestic (n = 110), visual (n = 18) and language (n = 7) predominate clinical phenotypes of Alzheimer’s disease. This revealed a consistent pattern of hypometabolism in parieto-frontal brain regions supporting executive functions with relative sparing of the medial temporal lobe (versus amnestic phenotype), occipital (versus visual phenotype) and left temporal (versus language phenotype). We propose that this progressive dysexecutive syndrome should be recognized as a distinct clinical phenotype disambiguated from behavioural presentations and not linked specifically to the frontal lobe or a particular anatomic substrate without further study. This clinical presentation can be due to Alzheimer’s disease but is likely not specific for any single aetiology. Diagnostic criteria are proposed to facilitate additional research into this understudied clinical presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, episodic memory impairment is more prominent in Alzheimer's disease than in behavioural variant frontotemporal dementia, although a dysexecutive or behavioural Alzheimer's disease variant is recognised.5”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Dysexecuitve syndrome, which involves impairment of working memory, cognitive flexibility and inhibitory control, is seen in progressive dementia syndrome due to Alzheimer disease. This syndrome is accompanied by frontoparietal hypometabolism as demonstrated by positron emission tomography104.”
From Cognitive and behavioural flexibility: Neural mechanisms and clinical considerations (2021) · cites this paper as [104]
In the citing paper
“Thus, these biomarkers can be used to identify patients who have frontal lobe dysfunction on the basis of AD pathology, rather than FTD, a condition sometimes called frontal variant AD.”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationStudies of interference in serial verbal reactions
Stroop, J. R. (1935) · Journal of Experimental Psychology · doi:10.1037/h0054651 · Cited by 18,622
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“Thal amyloid phase was performed using Ab immunohistochemistry (Thal et al., 2002) and Braak tangle stage was performed using tau immunohistochemistry (Braak and Braak, 1991).”
MethodMiyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D. (2000) · Cognitive Psychology · doi:10.1006/cogp.1999.0734 · Cited by 15,798
Diamond, A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143750 · Cited by 13,268
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationValidity of the Trail Making Test as an Indicator of Organic Brain Damage
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 7,928
Ashburner, J., & Friston, K. J. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.02.018 · Cited by 7,507
Baddeley, A. (1992) · Science · doi:10.1126/science.1736359 · Cited by 5,258
Working memory: Looking back and looking forward
Baddeley, A. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1201 · Cited by 5,200 · cited 2×
“This dysfunction is related to specific disruption of brain regions involved in executive functions (Baddeley, 2003) with relative sparing of brain regions supporting other functions (e.”
Background
Research works printed but not linked: 1
- Spreen, 1998, General intellectual ability and assessment of premorbid intelligence, A compendium of neuropsychological tests, 43
Cited by
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationFour distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Self-citationCognitive and behavioural flexibility: Neural mechanisms and clinical considerations
Uddin, L. Q. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00428-w · Cited by 698
Donanemab: Appropriate use recommendations
Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., et al. (2025) · The Journal of Prevention of Alzheimer's Disease · doi:10.1016/j.tjpad.2025.100150 · Cited by 278
Self-citation
Metadata
- Authors
- Townley, R. A., Graff-Radford, J., Mantyh, W. G., Botha, H., Polsinelli, A. J., Przybelski, S. A., Machulda, M. M., Makhlouf, A. T., Senjem, M. L., Murray, M. E., Reichard, R. R., Savica, R., Boeve, B. F., Drubach, D. A., Josephs, K. A., Knopman, D. S., Lowe, V. J., Jack, C. R., Petersen, R. C., & Jones, D. T.
- Affiliations
- Mayo Clinic (US)
- Department of Neurology Mayo Clinic, Rochester, MN 55902, USA
- Mayo Clinic in Florida (US)
- Corresponding author
- Jones, David T
- ORCID
- Venue
- Brain Communications
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-01-01
- Volume
- 2
- Issue
- 1
- Pages
- fcaa068-fcaa068
- ISSN
- 2632-1297 (ISSN-L)
- PMC
- PMC7325839
- OpenAlex
- W3031694559
- Cited by
- 145
- References
- 86
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 23 · 2023: 19 · 2022: 27 · 2021: 18 · 2020: 19
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Brain Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- AVID Radiopharmaceuticals, Inc
- NIH
- National Institutes of Health (P50 AG016574, U01 AG006786, R37 AG11378, R01 AG054449, R01 AG041851, R01 AG011378, R01 AG034676, R01 AG37491, R01 NS097495)
- Robert Wood Johnson Foundation
- Elsie and Marvin Dekelboum Family Foundation
- Liston Family Foundation
- Gerald and Henrietta Rauenhorst Foundation
- Foundation Dr. Corinne Schuler
- Alexander Family Alzheimer’s Disease Research
- Mayo Clinic, and the Mayo Foundation for Medical Education and Research
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Social Sciences › Psychology › Clinical Psychology › Historical and Modern Theater Studies
- Keywords
- Alzheimer's disease, executive dysfunction, early-onset Alzheimer's disease, clinical phenotype, FDG-PET hypometabolism, APOE ε4, cerebrospinal fluid biomarkers, EEG slowing, working memory, cognitive flexibility, inhibitory control, differential diagnosis of dementia, clinical criteria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.